Quantcast

Latest abdominal aortic aneurysm Stories

2010-10-27 15:01:00

IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs). Under the terms of the agreement, Endologix will acquire Nellix for $15 million in stock at closing, plus additional...

2010-10-25 08:00:00

IRVINE, Calif., Oct. 25 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Oppenheimer 21st Annual Healthcare Conference in New York, NY. Event: Oppenheimer's 21st Annual Healthcare Conference Date: Tuesday, November 2, 2010 Time: 12:00 p.m. ET An audio Web cast of the...

2010-10-18 15:15:00

IRVINE, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2010 financial results, which will take place on Wednesday, October 27, 2010 after the close of the market. Endologix will hold a conference call on Wednesday, October 27, 2010 at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for...

2010-10-18 15:01:00

IRVINE, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink® System for endovascular repair of abdominal aortic aneurysm (AAA) using an anatomical fixation technique with a suprarenal aortic extension. The trial demonstrated 100% procedural technical success,...

2010-09-28 08:00:00

IRVINE, Calif., Sept. 28 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the online publication of a long-term outcome analysis of abdominal aortic aneurysm (AAA) patients from the pivotal, multicenter, prospective clinical trials for the Company's Powerlink® System. The outcome analysis concluded that in the presence of a normal initial post-operative computed tomography angiography (CTA)...

2010-08-26 08:00:00

IRVINE, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it received CE Mark approval to market its expanded offering of Powerlink® stent graft products and PowerFit(TM) Aortic Extensions in the European Union. The Company expects to launch the products in a limited market release in Europe during the fourth quarter of 2010, followed by a full product launch in...

2010-08-16 10:30:00

IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has entered into a development agreement and exclusive license with Evasc Medical Systems Corp., for its balloon expandable stent technology. Evasc is a medical device development company located in Vancouver, B.C. The patented stent is made from cobalt chromium and is pre-mounted on an angioplasty balloon catheter for...

2010-08-11 15:10:00

IRVINE, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular...

2010-07-29 11:54:00

IRVINE, Calif., July 29 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its new PowerFit(TM) Aortic Extensions. The PowerFit extensions are designed to provide physicians with enhanced visibility under fluoroscopy to facilitate precise device placement during completion of the Anatomical Fixation endovascular repair of abdominal...

2010-07-13 15:30:00

IRVINE, Calif., July 13 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2010 financial results, which will take place on Thursday, July 22, 2010 after the close of the market. Endologix will hold a conference call on Thursday, July 22, 2010 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related